NKTR 214

Drug Profile

NKTR 214

Alternative Names: NKTR214

Latest Information Update: 20 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer Bristol-Myers Squibb; Nektar Therapeutics; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytokines
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sarcoma
  • Phase I/II Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Preclinical Lymphoma

Most Recent Events

  • 22 Feb 2018 Nektar Therapeutics plans the phase I/II REVEAL trial for Solid tumours (Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (NCT03435640)
  • 14 Feb 2018 Nektar Therapeutics and Bristol-Myers Squibb agree to co-promote and co-develop NKTR 214 in combination with nivolumab and ipilimumab for more than 20 indications across 9 tumour types
  • 14 Feb 2018 Nektar Therapeutics and Bristol-Myers Squibb plan a pivotal clinical trial for renal cell carcinoma and malignant melanoma in mid-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top